New Treatment for House Dust Mite
BEDMINSTER, New Jersey, January 10, 2018
Global pharmaceutical company, ALK today announced that its sublingual allergy immunotherapy (SLIT) tablet ODACTRA is now available through prescription in the US for those 18 years through 65 years of age who suffer from house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis.
Allergic rhinitis affects as many as 50 million Americans. It is estimated that up to 50% of these patients could be sensitized to house dust mites. HDM is the most prevalent indoor allergen in the US with 84% of homes having detectable levels of the allergen. Symptoms that result can be present year-round. In some cases, these adults may have symptoms that are not well controlled, experiencing persistent moderate to severe symptoms despite the use of symptom-relieving medications.
For some of these patients, ODACTRA may be a relevant treatment option that can reduce the symptoms of house dust mite induced allergic rhinitis as well as the need for symptom-reducing medications.
ODACTRA is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat house dust mite allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes. ODACTRA may be prescribed for persons 18 through 65 years of age who are allergic to house dust mites. ODACTRA is NOT a medication that gives immediate relief for symptoms of house dust mite allergy.
According to Bradley Chipps, MD, practicing Allergist & Immunologist and current President of American College of Allergy, Asthma and Immunology, “The introduction of ODACTRA, a fast dissolving immunotherapy tablet for the treatment of dust mite allergy, provides another treatment option for physicians and patients. Many patients find traditional immunotherapy, by shots, to be inconvenient. ODACTRA, is an effective, once a day tablet that provides another option for those patients who could benefit from immunotherapy.”
ODACTRA is the first HDM SLIT-tablet to be approved for use in the US and its safety and efficacy were evaluated in the world’s largest allergy immunotherapy clinical trial program, involving more than 6,000 patients.
David Skoner, MD, a practicing Allergist & Immunologist from Pittsburgh, PA, states, “Allergic rhinitis due to house dust mite sensitivity can have a significant impact on a patient’s quality of life. Patients may suffer from nasal and eye symptoms that can interrupt sleep, impact daily activities and result in lost work and school days. Allergy immunotherapy is widely recognized as an effective way of treating the underlying cause of allergic disease. With the availability of ODACTRA, HDM-induced allergic rhinitis patients can now be prescribed FDA-approved immunotherapy that does not require injections administered by a healthcare professional. Such a therapy is ideal for busy people, who lack time and previously lacked access to a convenient form of allergen immunotherapy”.